Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt No Debt
ARQL's Cash to Debt is ranked higher than
93% of the 1430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. ARQL: No Debt )
ARQL' s 10-Year Cash to Debt Range
Min: 2.7   Max: No Debt
Current: No Debt

Equity to Asset 0.64
ARQL's Equity to Asset is ranked higher than
70% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARQL: 0.64 )
ARQL' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.9
Current: 0.64

-0.16
0.9
F-Score: 1
Z-Score: -7.01
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -215.66
ARQL's Operating margin (%) is ranked higher than
65% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -90.24 vs. ARQL: -215.66 )
ARQL' s 10-Year Operating margin (%) Range
Min: -790.25   Max: 4.14
Current: -215.66

-790.25
4.14
Net-margin (%) -207.85
ARQL's Net-margin (%) is ranked higher than
65% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. ARQL: -207.85 )
ARQL' s 10-Year Net-margin (%) Range
Min: -582.35   Max: 7.66
Current: -207.85

-582.35
7.66
ROE (%) -47.12
ARQL's ROE (%) is ranked higher than
67% of the 1309 Companies
in the Global Biotechnology industry.

( Industry Median: -30.42 vs. ARQL: -47.12 )
ARQL' s 10-Year ROE (%) Range
Min: -141.91   Max: 4.84
Current: -47.12

-141.91
4.84
ROA (%) -29.13
ARQL's ROA (%) is ranked higher than
71% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: -25.96 vs. ARQL: -29.13 )
ARQL' s 10-Year ROA (%) Range
Min: -44.05   Max: 3.4
Current: -29.13

-44.05
3.4
ROC (Joel Greenblatt) (%) -3769.80
ARQL's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -335.68 vs. ARQL: -3769.80 )
ARQL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3849.33   Max: 6.14
Current: -3769.8

-3849.33
6.14
Revenue Growth (3Y)(%) -41.50
ARQL's Revenue Growth (3Y)(%) is ranked higher than
60% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. ARQL: -41.50 )
ARQL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.3   Max: 44.2
Current: -41.5

-61.3
44.2
EBITDA Growth (3Y)(%) 26.00
ARQL's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ARQL: 26.00 )
ARQL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.5   Max: 143.8
Current: 26

-45.5
143.8
EPS Growth (3Y)(%) 22.80
ARQL's EPS Growth (3Y)(%) is ranked higher than
89% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. ARQL: 22.80 )
ARQL' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.4   Max: 132.1
Current: 22.8

-48.4
132.1
» ARQL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ARQL Guru Trades in Q1 2014

Jim Simons 262,583 sh (+225.63%)
Chuck Royce 200,000 sh (+25.00%)
Jean-Marie Eveillard 2,843,599 sh (unchged)
Paul Tudor Jones 15,323 sh (-11.55%)
» More
Q2 2014

ARQL Guru Trades in Q2 2014

George Soros 78,600 sh (New)
Jim Simons 1,102,168 sh (+319.74%)
Paul Tudor Jones 15,323 sh (unchged)
Chuck Royce 200,000 sh (unchged)
Jean-Marie Eveillard 2,843,599 sh (unchged)
» More
Q3 2014

ARQL Guru Trades in Q3 2014

Jim Simons 1,120,035 sh (+1.62%)
Chuck Royce 200,000 sh (unchged)
Jean-Marie Eveillard 2,843,599 sh (unchged)
George Soros Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2014

ARQL Guru Trades in Q4 2014

Jean-Marie Eveillard 4,444,899 sh (+56.31%)
Jean-Marie Eveillard 4,444,899 sh (+56.31%)
Jim Simons 1,532,767 sh (+36.85%)
Chuck Royce 200,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARQL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.50
ARQL's P/B is ranked higher than
75% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 6.80 vs. ARQL: 3.50 )
ARQL' s 10-Year P/B Range
Min: 1.38   Max: 111.17
Current: 3.5

1.38
111.17
P/S 11.80
ARQL's P/S is ranked higher than
68% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 37.92 vs. ARQL: 11.80 )
ARQL' s 10-Year P/S Range
Min: 1.75   Max: 102.75
Current: 11.8

1.75
102.75
EV-to-EBIT -3.52
ARQL's EV-to-EBIT is ranked higher than
81% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ARQL: -3.52 )
ARQL' s 10-Year EV-to-EBIT Range
Min: -116.4   Max: -0.2
Current: -3.52

-116.4
-0.2
Current Ratio 3.34
ARQL's Current Ratio is ranked higher than
68% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ARQL: 3.34 )
ARQL' s 10-Year Current Ratio Range
Min: 1.48   Max: 7.45
Current: 3.34

1.48
7.45
Quick Ratio 3.34
ARQL's Quick Ratio is ranked higher than
69% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. ARQL: 3.34 )
ARQL' s 10-Year Quick Ratio Range
Min: 1.48   Max: 7.36
Current: 3.34

1.48
7.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.70
ARQL's Price/Net Cash is ranked higher than
92% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 105.00 vs. ARQL: 3.70 )
ARQL' s 10-Year Price/Net Cash Range
Min: 1.91   Max: 49.87
Current: 3.7

1.91
49.87
Price/Net Current Asset Value 3.70
ARQL's Price/Net Current Asset Value is ranked higher than
92% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. ARQL: 3.70 )
ARQL' s 10-Year Price/Net Current Asset Value Range
Min: 1.73   Max: 44.57
Current: 3.7

1.73
44.57
Price/Tangible Book 3.30
ARQL's Price/Tangible Book is ranked higher than
84% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 9.90 vs. ARQL: 3.30 )
ARQL' s 10-Year Price/Tangible Book Range
Min: 0.57   Max: 95.33
Current: 3.3

0.57
95.33
Price/Median PS Value 1.30
ARQL's Price/Median PS Value is ranked higher than
80% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. ARQL: 1.30 )
ARQL' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 3.6
Current: 1.3

0.11
3.6
Earnings Yield (Greenblatt) -29.40
ARQL's Earnings Yield (Greenblatt) is ranked lower than
62% of the 1388 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. ARQL: -29.40 )
ARQL' s 10-Year Earnings Yield (Greenblatt) Range
Min: -230.1   Max: 0
Current: -29.4

-230.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AQL.Germany,
ArQule, Inc., was organized as a Delaware corporation in 1993 in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform ("AKIP​TM") to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company and its partners, Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') and Kyowa Hakko Kirin Co., Ltd. ('Kyowa Hakko Kirin'), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate ('ATP') for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company's product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.
» More Articles for ARQL

Headlines

Articles On GuruFocus.com
comment on ARQL Nov 29 2012 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on ARQL May 01 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Reports Second Quarter 2009 Financial Results Aug 06 2009 
ArQule, Inc. to Report Second Quarter 2009 Financial Results on Thursday, August 6, 2009 Jul 30 2009 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 2,500 Shares May 15 2009 


More From Other Websites
Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog Apr 17 2015
Pacira Pharmaceuticals (PCRX) Falls: Stock Goes Down 9.7% - Tale of the Tape Apr 17 2015
Roche Acquires CAPP Medical to Strengthen Cancer Diagnosis - Analyst Blog Apr 14 2015
Pacira Announces Encouraging Data on Lead Drug Exparel - Analyst Blog Apr 13 2015
Shire's SHP625 Fails in Phase II, FDA Accepts Lifitegrast NDA - Analyst Blog Apr 10 2015
Zacks Rank #1 Additions for Thursday - Tale of the Tape Apr 09 2015
Shire Reaches Agreement with the FDA for ADHD Candidate - Analyst Blog Apr 08 2015
ArQule, Inc. to Present at 14th Annual Needham Healthcare Conference Apr 07 2015
Zacks Rank #1 Additions for Thursday - Tale of the Tape Apr 02 2015
Receptos, Inc. (RCPT) in Focus: Stock Jumps 5.2% - Tale of the Tape Apr 02 2015
Akebia Therapeutics (AKBA) in Focus: Stock Slumps 14.4% - Tale of the Tape Apr 02 2015
Zacks Rank #1 Additions for Friday - Tale of the Tape Mar 13 2015
Can The Uptrend Continue for ArQule (ARQL)? - Tale of the Tape Mar 12 2015
ARQULE INC Financials Mar 10 2015
ArQule (ARQL) Worth Watching: Stock Moves 7.4% Higher - Tale of the Tape Mar 09 2015
10-K for ArQule, Inc. Mar 06 2015
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 04 2015
ArQule Reports Fiscal 2014 Year End and Fourth Quarter Results Mar 04 2015
ArQule reports 4Q loss Mar 04 2015
ArQule reports 4Q loss Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK